KLL3: Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)
The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL) is studied.
|Condition or Disease||Intervention/Treatment||Phase|
The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL)is studied in patients and healthly controls.
Arms and Interventions
Primary Outcome Measures
- IDO activity and expression measured by kynurenine/tryptophan ratio in serum and by PCR in peripheral blood mononuclear cells. [3 months]
Indoleamine 2,3 -dioxygenase (IDO) activity in patients with CLL was measured by the serum kynurenine/tryptophan (kyn/trp) ratio and - the expression of INDO (encoding IDO enzyme) and INDOL1 (encoding IDO2 enzyme) genes in peripheral blood mononuclear cells via TaqMan real-time PCR.
- Patients with CLL and lymphocyte count > 10 x 109/l
- Acute infection
Contacts and Locations
|1||Tampere university Hospital||Tampere||Finland||33521|
Sponsors and Collaborators
- Tampere University Hospital
- Principal Investigator: Marjatta Sinisalo, MD, PhD, Tampere University Hospital
Study Documents (Full-Text)None provided.